Business Description
Scandion Oncology AS
ISIN : DK0061031895
Share Class Description:
STU:8VY: Ordinary SharesCompare
Compare
Traded in other countries / regions
SCOL.Sweden8VY.Germany IPO Date
2021-02-10Description
Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 90.2 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.01 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -19.9 | |||||
| 3-Year EPS without NRI Growth Rate | -26.1 | |||||
| 3-Year FCF Growth Rate | -34.8 | |||||
| 3-Year Book Growth Rate | -44.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.03 | |||||
| 9-Day RSI | 33.16 | |||||
| 14-Day RSI | 34.36 | |||||
| 6-1 Month Momentum % | -34.02 | |||||
| 12-1 Month Momentum % | -76.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.82 | |||||
| Quick Ratio | 4.82 | |||||
| Cash Ratio | 3.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.2 | |||||
| Shareholder Yield % | -171.68 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -105.89 | |||||
| ROA % | -89.22 | |||||
| ROIC % | -337.96 | |||||
| ROC (Joel Greenblatt) % | -2084.6 | |||||
| ROCE % | -123.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.46 | |||||
| Price-to-Tangible-Book | 0.28 | |||||
| EV-to-EBIT | 0.09 | |||||
| EV-to-EBITDA | 0.09 | |||||
| EV-to-Forward-EBITDA | -0.06 | |||||
| EV-to-Forward-Revenue | 2.3 | |||||
| EV-to-FCF | 0.1 | |||||
| Price-to-Net-Current-Asset-Value | 0.56 | |||||
| Price-to-Net-Cash | 0.56 | |||||
| Earnings Yield (Greenblatt) % | 1105.02 | |||||
| FCF Yield % | -308.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scandion Oncology AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.027 | ||
| Beta | 2.15 | ||
| Volatility % | 179.89 | ||
| 14-Day RSI | 34.36 | ||
| 14-Day ATR (€) | 0.000408 | ||
| 20-Day SMA (€) | 0.00646 | ||
| 12-1 Month Momentum % | -76.18 | ||
| 52-Week Range (€) | 0.0054 - 0.143984 | ||
| Shares Outstanding (Mil) | 234.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scandion Oncology AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scandion Oncology AS Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Scandion Oncology AS Frequently Asked Questions
What is Scandion Oncology AS(STU:8VY)'s stock price today?
The current price of STU:8VY is €0.01. The 52 week high of STU:8VY is €0.14 and 52 week low is €0.01.
When is next earnings date of Scandion Oncology AS(STU:8VY)?
The next earnings date of Scandion Oncology AS(STU:8VY) is 2025-02-28.
Does Scandion Oncology AS(STU:8VY) pay dividends? If so, how much?
Scandion Oncology AS(STU:8VY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers